Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01498874 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
- 19
- Study locations
NCT01498874: Completed Phase 2 study of Acne Vulgaris, sponsored by Xoma (US).
NCT01498874 is a Phase 2 study of Acne Vulgaris that has completed, run by Xoma (US). The registered enrollment target is 127 participants, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (53% lower). The trial reports 19 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01498874, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG gevokizumab
Study Locations (19)
North Carolina
- - Charlotte
- - High Point
- - Raleigh
Texas
- - Arlington
- - Austin
- - Houston
California
- - Riverside
- - San Diego
Arkansas
- - Hot Springs
Colorado
- - Denver
Connecticut
- - New Haven
Michigan
- - Bay City
Minnesota
- - Fridley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT01498874 record still lists
NCT01498874 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01498874 lists 19 locations in 14 states (North Carolina, Texas, California).
Frequently Asked Questions
What is clinical trial NCT01498874 about?
NCT01498874 is a clinical study titled "Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris". The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.
What is the current status of trial NCT01498874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2011-12. Estimated completion is 2013-06.
What conditions does trial NCT01498874 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT01498874?
The interventions under investigation include: Placebo (DRUG), gevokizumab (DRUG).
Who is sponsoring clinical trial NCT01498874?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01498874 being conducted?
This trial has 19 study locations across Arkansas, California, Colorado, Connecticut, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01498874's enrollment target sits among peer trials
127 33rd of 67 higher than 35 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia